# File Descriptions

All datasets are formatted to contain antibody variable domain sequence (heavy chain + light chain or heavy chain only), and one or more fitness metric.

| Filename                                | Size | Assay/Units          | Description                   | Publication                                                                                       | Year | Direction of favorable values| 
|-----------------------------------------|------|---------------------|-------------------------------|-------------------------------------------------------------------------------------------------|------| -------- |
| garbinski2023_tm1.csv                    | 86   | Tm1 (nanoDSF)       | None                          | None                                                                                            | 2023 | ↑ | 
| hie2023efficient_C143_Tm.csv             | 2    | Tm                  | C143                          | [Efficient evolution of human antibodies from general protein language models](https://doi.org/10.1038/s41587-023-01763-2) | 2023 | ↑ | 
| hie2023efficient_MEDIUCA_Tm.csv          | 6    | Tm                  | MEDIUCA                       | [Efficient evolution of human antibodies from general protein language models](https://doi.org/10.1038/s41587-023-01763-2) | 2023 | ↑ | 
| hie2023efficient_MEDI_Tm.csv              | 2    | Tm                  | MEDI                          | [Efficient evolution of human antibodies from general protein language models](https://doi.org/10.1038/s41587-023-01763-2) | 2023 | ↑ | 
| hie2023efficient_REGN10987_Tm.csv        | 8    | Tm                  | REGN10987                     | [Efficient evolution of human antibodies from general protein language models](https://doi.org/10.1038/s41587-023-01763-2) | 2023 | ↑ | 
| hie2023efficient_S309_Tm.csv              | 10   | Tm                  | S309                          | [Efficient evolution of human antibodies from general protein language models](https://doi.org/10.1038/s41587-023-01763-2) | 2023 | ↑ | 
| hie2023efficient_mAb114UCA_Tm.csv        | 2    | Tm                  | mAb114UCA                     | [Efficient evolution of human antibodies from general protein language models](https://doi.org/10.1038/s41587-023-01763-2) | 2023 | ↑ | 
| hie2023efficient_mAb114_Tm.csv            | 7    | Tm                  | mAb114                        | [Efficient evolution of human antibodies from general protein language models](https://doi.org/10.1038/s41587-023-01763-2) | 2023 | ↑ | 
| hutchinson2023enhancement_multitm1_igg.csv | 15   | Tm1 (°C) IgG        | Fv                            | [Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen](https://doi.org/10.1080/19420862.2024.2362775) | 2024 | ↑ | 
| hutchinson2023enhancement_singletm1_igg.csv | 23   | Tm1 (°C) IgG        | Fv                            | [Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen](https://doi.org/10.1080/19420862.2024.2362775) | 2024 | ↑ | 
| hutchinson2023enhancement_top200tm1_igg.csv | 192  | Tm1 (°C) IgG        | Fv                            | [Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen](https://doi.org/10.1080/19420862.2024.2362775) | 2024 | ↑ | 
| hutchinson2023enhancement_top27tm1_igg.csv | 28   | Tm1 (°C) IgG        | Fv                            | [Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen](https://doi.org/10.1080/19420862.2024.2362775) | 2024 | ↑ | 
| jain2017biophysical_Tm.csv               | 137  | Fab Tm by DSF (°C)  | clinical stage therapeutic, Fv | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 | ↑ | 
| jain2024assessment_Tm.csv                | 43   | Fab Tm by DSF (°C)  | germline, Fv                 | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 | ↑ | 
| rosace2023automated_tm1_adalimumab.csv  | 14   | Tm (C) rep1         | Adalimumab, Fv               | [Automated optimisation of solubility and conformational stability of antibodies and proteins](https://doi.org/10.1038/s41467-023-37668-6) | 2022 | ↑ | 
| rosace2023automated_tm1_golimumab.csv   | 5    | Tm (C) rep1         | Golimumab, Fv               | [Automated optimisation of solubility and conformational stability of antibodies and proteins](https://doi.org/10.1038/s41467-023-37668-6) | 2022 | ↑ | 
| shanehsazzadeh2023unlocking_DLS.csv     | 13   | DLS - Cumulant PDI  | Trastuzumab, Fv             | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 | ↑ | 
| shanehsazzadeh2023unlocking_DSF1.csv    | 13   | DSF - IP #1 (oC)    | Trastuzumab, Fv             | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 | ↑ | 
| shanehsazzadeh2023unlocking_DSF2.csv    | 13   | DSF - IP #2 (oC)    | Trastuzumab, Fv             | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 | ↑ | 
| sulea2019assisted_sdAb_tm.csv            | 33   | Tm                  | sdAb                        | [Assisted Design of Antibody and Protein Therapeutics (ADAPT)](https://doi.org/10.1371/journal.pone.0181490) | 2019 | ↑ | 
| tresanco2023nbthermo_tm.csv              | 673  | Tm                  | Nanobody                    | [NbThermo: a new thermostability database for nanobodies](https://doi.org/10.1093/database/baad021) | 2023 | ↑ | 

# Additional data not included

`Ginkgo Datapoints developability assays` - https://datapoints.ginkgo.bio/what-we-do/antibody-developability



